A new pharmaceutical compound called Retatrutide has shown promising results in treating obesity and type 2 diabetes, according to recent clinical trial data. Developed as a weekly injectable medication, Retatrutide, sometimes referred to as "Reta" or nicknamed "Godzilla" due to its potent effects, may offer significant advantages over existing treatments like Mounjaro.

The multi-national study involved 1,152 overweight or obese adults with type 2 diabetes from eight countries, who were assigned to receive weekly doses of Retatrutide at 4 mg, 9 mg, or 12 mg, or a placebo, coupled with guidelines on diet and exercise. Over a period of 80 weeks, participants receiving the highest 12 mg dosage achieved an average weight loss approaching 20% of their body weight, with nearly one-third shedding at least 25%. Those on the 9 mg and 4 mg doses lost about 17% and 12%, respectively, while the placebo group experienced a 5% average reduction.

In addition to weight reduction, Retatrutide demonstrated considerable improvements in blood sugar control. Approximately 75% of patients receiving the 12 mg dose attained glycated hemoglobin (HbA1c) levels at or below the threshold typically used for diabetes diagnosis, compared with 29% in the placebo cohort. The trial also reported benefits in cardiovascular risk markers, including reductions in low-density lipoprotein cholesterol and inflammation.

Retatrutide belongs to the glucagon-like peptide-1 (GLP-1) receptor agonist class of drugs, which includes treatments such as Mounjaro and Ozempic. Like these medications, the new drug was associated with side effects, most commonly nausea and diarrhea. Some participants—7% of those on the highest dose—reported abnormal skin sensations like burning or discomfort.

While Retatrutide has not yet received regulatory approval for use on the UK's National Health Service (NHS), experts suggest it could become available for prescription within the next three years if it secures licensing from health authorities. The drug's potential to deliver substantial weight loss alongside improved diabetes management has led researchers to describe it as a potential breakthrough for conditions linked to obesity, including heart disease and osteoarthritis.